Table 4.
Patients who had recurrent iMN and received rituximab treatment: Patient characteristics at the time of rituximab administration
| Variable | Patient 8 | Patient 9 | Patient 10 | Patient 11 |
|---|---|---|---|---|
| Time since renal transplantation | 20 months | 20 months | 36 weeks | 15.2 years |
| Time since diagnosis of recurrent MN | 6 months | 5 days | 34 weeks | 3 weeks |
| BP (mmHg) | 130/88 | 150/90 | 130/80 | 130/90 |
| Edema | 2 to 3+ | Trace | Trace | 0 |
| Immunosuppressive regimen | Tacrolimus, MMF | Tacrolimus, azathioprine | Tacrolimus MMF | Cyclosporine, azathioprine, prednisone |
| ARB | Losartan | Losartan | Candesartan | |
| Diuretics | Furosemide | |||
| Statins | Simvastatin | Atorvastatin | ||
| Others | Amlodipine, allopurinol, testosterone, propranolol, gabapentin, epoietin alfa | ASA, calcium carbonate, labetalol | Amlodipine, ASA, nadolol |
ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; MMF, mycophenolate mofetil.